Caroline S. Foo

Leuven, VLG 3000, Belgium

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Integrating artificial intelligence-based epitope prediction in a SARS-CoV-2 antibody discovery pipeline: caution is warranted.

Integrating artificial intelligence-based epitope prediction in a SARS-CoV-2 antibody discovery pipeline: caution is warranted.

Journal: EBioMedicine
Published: May 01, 2023

A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection.

A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection.

Journal: Journal of virology
Published: August 04, 2022

Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19.

Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19.

Journal: Microorganisms
Published: July 07, 2022

Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys.

Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys.

Journal: Nature microbiology
Published: June 08, 2022

Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters.

Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters.

Journal: Nature communications
Published: March 22, 2022

Ivermectin Does Not Protect against SARS-CoV-2 Infection in the Syrian Hamster Model.

Ivermectin Does Not Protect against SARS-CoV-2 Infection in the Syrian Hamster Model.

Journal: Microorganisms
Published: February 23, 2022

A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity.

A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: February 11, 2022

HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect.

HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect.

Journal: Antiviral research
Published: February 10, 2022

The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters.

The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters.

Journal: Antiviral research
Published: December 31, 2021

Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model.

Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model.

Journal: iScience
Published: December 10, 2021

The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern.

The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern.

Journal: Nature communications
Published: November 04, 2021

An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models.

An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models.

Journal: Science translational medicine
Published: October 05, 2021
Showing 1-12 of 22

Last Updated: 09/26/2026